The recent report titled Global Agriculture Biotechnology Market Size, Status and Forecast 2020-2026 offered by Researchmoz.us, comprises of a comprehensive investigation into the geographical landscape, industry size along with the revenue estimation of the business. Additionally, the report also highlights the challenges impeding market growth and expansion strategies employed by leading companies in the Agriculture Biotechnology market.

This is the most recent report inclusive of the COVID-19 effects on the functioning of the market. It is well known that some changes, for the worse, were administered by the pandemic on all industries. The current scenario of the business sector and pandemics impact on the past and future of the industry are covered in this report.

Grab A Free Sample Copy of the Agriculture Biotechnology Market Report

In market segmentation by manufacturers, the report covers the following companies : ADAMA Agricultural Solutions, Vilmorin, Bayer, Biocentury Transgene, Certis, DowDuPont, Eurofins, Evogene, Global Bio-chem Technology, Syngenta, KWS Saat, Marina Biotech, Monsanto and among others.

Exploring Growth Rate Over a Period:

Business owners looking to scale up their business can refer this report that contains data regarding the rise in sales within a given consumer base for the forecast period, 2020 to 2026. Product owners can use this information along with the driving factors such as demographics and revenue generated from other products discussed in the report to get a better analysis of their products and services. Besides, the research analysts have compared the market growth rate with the product sales to enable business owners to determine the success or failure of a specific product or service.

Agriculture Biotechnology Market is segmented as below:

Analysis by Application:

Analysis by Product Type:

Global Agriculture Biotechnology Market Report 2020 Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global Agriculture Biotechnology industry.

The Report at a Glance

The Agriculture Biotechnology market report focuses on the economic developments and consumer spending trends across different countries for the forecast period 2020 to 2026. The research further reveals which countries and regions will have a better standing in the years to come. Apart from this, the study talks about the growth rate, market share as well as the recent developments in the Agriculture Biotechnology industry worldwide. Besides, the special mention of major market players adds importance to the overall market study.

Market segment by Region/Country including:

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert

The research provides answers to the following key questions:

Why Choose Researchmoz?

!!! Limited Time DISCOUNT Available!!! Get Your Copy at Discounted Price

To summarize, the global Agriculture Biotechnology market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

.

Contact Us:

ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email: [emailprotected]Follow us on LinkedIn @ http://bit.ly/2RtaFUo

Follow me on : https://marketnews-24.blogspot.com/

Visit link:
Agriculture Biotechnology Market Forecasts 2020-2026 : Growth Analysis By Key Drivers, Regions, Sorts and Applications - PRnews Leader

Biotechnology Reagents Market Growth across application territories and rising interest for the item across significant geologies principally Asia Pacific is relied upon to help the development of the market all through the gauge time frame, i.e., 2020 to 2027. There are some different factors too that are driving the development of the market and along these lines this market is required to accomplish a critical development rate during the conjecture time frame. The market is sectioned by type, by end-use and furthermore by significant geology to be specific Europe, Rest of the World, Asia Pacific and North America. South America, Middle East and Africa are the inclusion under Rest of the World while we have secured Italy, France, Germany, Spain and UK under Europe. The nations that have been ordered under Asia Pacific are India, South Korea, Taiwan, China, and Japan among others.

Get Sample ToC to understand the CORONA Virus/COVID19 impact and be smart in redefining business [emailprotected] https://www.researchkraft.com/request-sample/1113146

This unmistakable statistical surveying report uncovering subtleties on the Global Biotechnology Reagents Market is a committed report aggregation to empower perusers with another point of view so as to make new development guides. The report minutely floats across past turns of events and occasions other than minutely watching present improvements to support future-prepared market carefulness.A very much made datasheet out of exact dominate sheet information, including significant subtleties from across quantitative information sources that have been conveniently accumulated from numerous mathematical information sources and incorporated in complex dominate design for simple access.

The Top players are:

Life Technologies (U.S.), Bio-Rad (U.S.), Thermo Fisher Scientific (U.S.), Water Corporation (U.S.), Sigma-Aldrich (U.S.), Agilent Technologies Inc. (U.S.), Betcon Dickinson (U.S.), Beckman Coulter (U.S.), Roche (Switzerland), Abbott (U.S.)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.researchkraft.com/check-discount/1113146

Research Objective:

Market Segmentation:

Market Segmentation:

The key regions covered in the Biotechnology Reagents market report are:

Key target audience:

Request For Exclusive Sample PDF along with few company [emailprotected] https://www.researchkraft.com/send-an-enquiry/1113146

Contact Us: 888-213-4282

Email: [emailprotected]

Excerpt from:
Biotechnology Reagents Market 2020-2027 How the Market Will Witness Substantial Growth in the Upcoming years Life Technologies (US), Bio-Rad (US),...

A rating of 85 puts SpringWorks Therapeutics Inc (SWTX) near the top of the Biotechnology industry according to InvestorsObserver. SpringWorks Therapeutics Inc's score of 85 means it scores higher than 85% of stocks in the industry. SpringWorks Therapeutics Inc also received an overall rating of 69, putting it above 69% of all stocks. Biotechnology is ranked 23 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

SpringWorks Therapeutics Inc (SWTX) stock is trading at $55.01 as of 11:44 AM on Friday, Oct 9, an increase of $3.03, or 5.83% from the previous closing price of $51.98. The stock has traded between $52.79 and $56.45 so far today. Volume today is 339,767 compared to average volume of 364,745.

Click Here to get the full Stock Score Report on SpringWorks Therapeutics Inc (SWTX) Stock.

Originally posted here:
Where Does SpringWorks Therapeutics Inc (SWTX) Stock Fall in the Biotechnology Field? - InvestorsObserver

Abeona Therapeutics Inc (ABEO) is near the middle in its industry group according to InvestorsObserver. ABEO gets an overall rating of 42. That means it scores higher than 42 percent of stocks. Abeona Therapeutics Inc gets a 34 rank in the Biotechnology industry. Biotechnology is number 23 out of 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 42 would rank higher than 42 percent of all stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Abeona Therapeutics Inc (ABEO) stock is trading at $1.49 as of 11:29 AM on Friday, Oct 9, a rise of $0.11, or 7.61% from the previous closing price of $1.38. The stock has traded between $1.40 and $1.58 so far today. Volume today is 2,298,910 compared to average volume of 2,423,598.

Click Here to get the full Stock Score Report on Abeona Therapeutics Inc (ABEO) Stock.

More:
Where Does Abeona Therapeutics Inc (ABEO) Stock Fall in the Biotechnology Field? - InvestorsObserver

SAN DIEGO--(BUSINESS WIRE)--Allele Biotechnology and Pharmaceuticals, Inc. (Allele), a San Diego-based company focused on developing and adapting cutting edge technology for clinical and therapeutic use, filed two patent infringement lawsuits today one in New York against Regeneron Pharmaceuticals and the other in California against Pfizer and BioNTech. Both complaints address the infringement of Alleles patented mNeonGreen technology, an important reagent used in the development of therapeutics for COVID-19.

Alleles mNeonGreen protein is considered the worlds brightest monomeric fluorescent protein, and the technology behind that protein was patented in 2019. Prominent scientific journals have touted the use of mNeonGreen as the gold standard for use in assays testing neutralizing antibody and vaccine candidates. Regeneron, Pfizer, and BioNTech used mNeonGreen commercially without authorization from Allele.

I am pleased that mNeonGreen has played a pivotal role in the fight against COVID-19. In no way does Allele want to prohibit, or slow down development of vaccines or therapeutics discovered using this technology, says Dr. Jiwu Wang, Founder and CEO of Allele. Our goal is to have these companies recognize, as many others have before them, the hard work that went in to developing this technology and to respect our intellectual property.

Hundreds of organizations and universities have active licenses to use Alleles mNeonGreen technology. According to the complaint, Allele reached out to Regeneron on multiple occasions to negotiate a license on reasonable terms, but all of its requests went unanswered. In fact, no defendant sought any permission in advance of using mNeonGreen to obtain breakthrough successes in developing and testing their vaccines.

The purpose of these lawsuits is to maintain Allele's patent rights and to ensure that an agreement can be put in place to protect the rights of current and future licensees, says Dan Catron, Executive Director, Licensing and Business Development for Allele.

Perkins Coie LLP is representing Allele in the New York filing. Troutman Pepper Hamilton Sanders LLP is representing Allele in the California lawsuits.

About Allele Biotechnology and Pharmaceuticals Inc.

Established in 1999, Allele Biotechnology has focused on developing and adapting cutting edge technology for clinical and therapeutic use. Allele has worked on biological advancements that have been at the forefront of molecular biology research, including RNA interference, fluorescent proteins, induced Pluripotent Stem Cells (iPSCs), and camelid-derived, single-domain nanoantibodies. With the advent of the global pandemic, Allele initiated the development of a series of llama nanoantibodies against SARS-CoV-2, the virus responsible for COVID-19. To learn more, go to https://www.allelebiotech.com.

Go here to see the original:
Allele Biotechnology and Pharmaceuticals Files Two Lawsuits for Patent Infringement for the Unauthorized Use of mNeonGreen in Development and Testing...

Provention Bio Inc (PRVB) is near the top in its industry group according to InvestorsObserver. PRVB gets an overall rating of 68. That means it scores higher than 68 percent of stocks. Provention Bio Inc gets a 86 rank in the Biotechnology industry. Biotechnology is number 27 out of 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Provention Bio Inc (PRVB) stock is trading at $14.48 as of 2:24 PM on Monday, Oct 5, a rise of $1.12, or 8.38% from the previous closing price of $13.36. The stock has traded between $13.37 and $14.70 so far today. Volume today is less active than usual. So far 362,155 shares have traded compared to average volume of 632,466 shares.

Click Here to get the full Stock Score Report on Provention Bio Inc (PRVB) Stock.

See the original post:
Should You Buy Provention Bio Inc (PRVB) in Biotechnology Industry? - InvestorsObserver

Arcturus Therapeutics Holdings Inc (ARCT) is near the top in its industry group according to InvestorsObserver. ARCT gets an overall rating of 70. That means it scores higher than 70 percent of stocks. Arcturus Therapeutics Holdings Inc gets a 87 rank in the Biotechnology industry. Biotechnology is number 27 out of 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 70 would rank higher than 70 percent of all stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Arcturus Therapeutics Holdings Inc (ARCT) stock is trading at $49.99 as of 1:11 PM on Monday, Oct 5, a rise of $7.20, or 16.83% from the previous closing price of $42.79. The stock has traded between $43.22 and $50.50 so far today. Volume today is low. So far 326,119 shares have traded compared to average volume of 737,857 shares.

Click Here to get the full Stock Score Report on Arcturus Therapeutics Holdings Inc (ARCT) Stock.

Continue reading here:
Where Does Arcturus Therapeutics Holdings Inc (ARCT) Stock Fall in the Biotechnology Field? - InvestorsObserver

FLORHAM PARK, N.J., Sept. 28, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (PDS Biotech or the Company) (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology, today announced that its Chief Medical Officer, Lauren V. Wood, M.D. will present key data from the companys previously reported Phase 1 trial of PDS0101 and planned Phase 2 clinical studies in patients with advanced HPV-associated malignancies at the World Vaccine Congress, being held virtually September 28 October 1, 2020.

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology platform. Versamune effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations, and assumptions and include statements regarding the proposed public offering and anticipated closing. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including market conditions, whether the proposed offering is completed, the satisfaction of customary closing conditions related to the proposed offering and the other factors described in PDS Biotechs filings with the SEC. The information in this release is provided only as of the date of this release, and PDS Biotech undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

Media & Investor Relations Contact:

Deanne RandolphPDS BiotechnologyPhone: +1 (908) 517-3613Email: drandolph@pdsbiotech.com

James SaliernoThe Ruth GroupPhone: +1 (646) 536-7028 / +1 (973) 255-8361Email: jsalierno@theruthgroup.com

Here is the original post:
PDS Biotechnology to Present Results from its Phase 1 Trial of PDS0101 and the Phase 2 Clinical Strategy in Patients with Advanced HPV-Associated...

Even when a business is losing money, its possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly.

So should G&E Herbal Biotechnology (GTSM:4911) shareholders be worried about its cash burn? In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth. The first step is to compare its cash burn with its cash reserves, to give us its cash runway.

Check out our latest analysis for G&E Herbal Biotechnology

You can calculate a companys cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. As at June 2020, G&E Herbal Biotechnology had cash of NT$122m and no debt. Looking at the last year, the company burnt through NT$12m. That means it had a cash runway of about 9.8 years as of June 2020. Even though this is but one measure of the companys cash burn, the thought of such a long cash runway warms our bellies in a comforting way. The image below shows how its cash balance has been changing over the last few years.

Whilst its great to see that G&E Herbal Biotechnology has already begun generating revenue from operations, last year it only produced NT$19m, so we dont think it is generating significant revenue, at this point. As a result, we think its a bit early to focus on the revenue growth, so well limit ourselves to looking at how the cash burn is changing over time. Notably, its cash burn was actually down by 63% in the last year, which is a real positive in terms of resilience, but uninspiring when it comes to investment for growth. G&E Herbal Biotechnology makes us a little nervous due to its lack of substantial operating revenue. We prefer most of the stocks on this list of stocks that analysts expect to grow.

Theres no doubt G&E Herbal Biotechnologys rapidly reducing cash burn brings comfort, but even if its only hypothetical, its always worth asking how easily it could raise more money to fund further growth. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Many companies end up issuing new shares to fund future growth. By looking at a companys cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another years cash burn.

G&E Herbal Biotechnology has a market capitalisation of NT$2.2b and burnt through NT$12m last year, which is 0.6% of the companys market value. So it could almost certainly just borrow a little to fund another years growth, or else easily raise the cash by issuing a few shares.

As you can probably tell by now, were not too worried about G&E Herbal Biotechnologys cash burn. In particular, we think its cash runway stands out as evidence that the company is well on top of its spending. But its fair to say that its cash burn reduction was also very reassuring. After taking into account the various metrics mentioned in this report, were pretty comfortable with how the company is spending its cash, as it seems on track to meet its needs over the medium term. On another note, G&E Herbal Biotechnology has 4 warning signs (and 2 which dont sit too well with us) we think you should know about.

Of course G&E Herbal Biotechnology may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

PromotedWhen trading G&E Herbal Biotechnology or any other investment, use the platform considered by many to be the Professionals Gateway to the Worlds Market, Interactive Brokers. You get the lowest-cost* trading on stocks, options, futures, forex, bonds and funds worldwide from a single integrated account.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. *Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

Original post:
Companies Like G&E Herbal Biotechnology (GTSM:4911) Can Afford To Invest In Growth - Simply Wall St

New York, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Agricultural Biotechnology Market Research Report by Crop Type, by Type, by Product Type, by Mode of Application, by Function, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05968805/?utm_source=GNW

The Global Agricultural Biotechnology Market is expected to grow from USD 31,158.52 Million in 2019 to USD 56,315.91 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 10.36%.

Market Segmentation & Coverage:This research report categorizes the Agricultural Biotechnology to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Crop Type, the Agricultural Biotechnology Market studied across Cereals & Grains, Fruits & Vegetables, Macroindicators, and Oilseeds & Pulses.

Based on Type, the Agricultural Biotechnology Market studied across Animals, Microbes, and Plants. The Animals further studied across Conventional Techniques, Established Genetic Modification, and New Breeding Techniques. The Microbes further studied across Conventional Techniques, Established Genetic Modification, and New Breeding Techniques. The Plants further studied across Conventional Techniques, Established Genetic Modification, and New Breeding Techniques.

Based on Product Type, the Agricultural Biotechnology Market studied across Macrobials, Microbials, Natural Products, and Semichemicals.

Based on Mode of Application , the Agricultural Biotechnology Market studied across Foliar Spray, Seed Treatment, and Soil Treatment.

Based on Function, the Agricultural Biotechnology Market studied across Crop Enhancement and Crop protection. The Crop Enhancement further studied across Biofertilizers and Biostimulants. The Crop protection further studied across Biocontrol.

Based on Application, the Agricultural Biotechnology Market studied across Antibiotic Development, Biofuels, Flower Culturing, Nutritional Supplements, Transgenic Crops & Animals, and Vaccine Development.

"The Asia-Pacific is projected to witness the highest growth during the forecast period"

Based on Geography, the Agricultural Biotechnology Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. The Americas commanded the largest size in the Agricultural Biotechnology Market in 2019. On the other hand, the Asia-Pacific is expected to grow at the fastest CAGR during the forecast period.

Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Agricultural Biotechnology Market including ADAMA Agricultural Solutions Ltd., BASF SE, Bayer AG, Benson Hill Biosystems, Inc., Certis U.S.A. LLC, China National Chemical Corporation Ltd., Corteva, Inc., DowDuPont Inc., Evogene Ltd., Global Bio-chem Technology Group Company Limited., Groupe Limagrain Holding, KWS SAAT SE & Co. KGaA, Marrone Bio Innovations, Inc., Mitsui & Co., Ltd., Nufarm Limited, Performance Plants Inc., Syngenta AG, The Monsanto Company, Valent BioSciences LLC, VILMORIN & CIE, and Yield10 Biosciences Inc..

FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Agricultural Biotechnology Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:1. What is the market size and forecast of the Global Agricultural Biotechnology Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Agricultural Biotechnology Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Agricultural Biotechnology Market?4. What is the competitive strategic window for opportunities in the Global Agricultural Biotechnology Market?5. What are the technology trends and regulatory frameworks in the Global Agricultural Biotechnology Market?6. What are the modes and strategic moves considered suitable for entering the Global Agricultural Biotechnology Market?Read the full report: https://www.reportlinker.com/p05968805/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Follow this link:
Agricultural Biotechnology Market Research Report by Crop Type, by Type, by Product Type, by Mode of Application, by Function, by Application - Global...

Government supports Research Institutes, Central & State Agriculture Universities for competitive R&D and demonstration activities in Agriculture Biotechnology including organic farming. The Biotech-Krishi Innovation Science Application Network (Biotech-KISAN) programme also focuses on taking innovative technologies to the farmers. The activity has been supported across the country including Aspirational Districts. During the last three years, approximately Rs. 310 crores has been invested for supporting the use of Biotechnology in agriculture including organic farming through these programmes.

Twenty States and two Union Territories have prepared their own Biotechnology policy. (Details are provided in Annexure I.)

Government through Department of Biotechnology (DBT) has implemented integrated Human Resource Development Program in Biotechnology to provide Biotechnology trained personnel in various fields including agriculture. Some of the major programmes include Postgraduate Teaching Program, DBT-Junior Research Fellowship Program, DBT- Research Associate ship and DBT-Biotechnology industry Training Program (Apprenticeship) Program for skilled and trained manpower etc. These programmes are supported across the country.

Annexure-I

The details of States/UTs having Biotechnology policy are as follows:

This information was given by the UnionMinister of Science and Technology, Earth Sciences and Health and Family Welfare, Dr Harsh Vardhanin a written reply in Lok Sabha today.

The rest is here:
Twenty States and two Union Territories have prepared their own Biotechnology policy - India Education Diary

Historically, biotech has been primarily associated with food, addressing such issues as malnutrition and famine, writes Brian Colwell in this article published by Genetic Literacy Project (GLP).

Today, biotechnology is most often associated with the development of drugs, Colwell writes. But drugs are hardly the future of biotech. Weve entered the Fourth Industrial Revolution, and genetics are on a new level. Biotech is paving a way for a future open to imagination, and thats kind of scary. The next ten years will surely prove exciting as artificial intelligence and biotechnology merge man and machine

Colwell divides the history intoo three distinct phases: Ancient Biotechnology, Classical Biotechnology and Modern Biotechnology.

Colwell concludes his article saying: Today, biotechnology is being used in countless areas including agriculture, bioremediation and forensics, where DNA fingerprinting is a common practice. Industry and medicine alike use the techniques of PCR, immunoassays and recombinant DNA. Genetic manipulation has been the primary reason that biology is now seen as the science of the future and biotechnology as one of the leading industries.

Source: Genetic Literacy Project. Read the full article hereAuthor: Brian Colwell is a technology futuristwith an investment thesis focused on disruptions in this next Industrial revolution. His research areas includeagricultural,biotechnology and artificial intelligence. Follow@BrianDColwellon Twitterand at hiswebsite.

Related

View post:
Biotechnology timeline: Humans have manipulated genes since the dawn of civilization - Potato News Today

A new report on Biotechnology market that provides a comprehensive review of this industry with respect to the driving forces influencing the market size. Comprising the current and future trends defining the dynamics of this industry vertical, this report also incorporates the regional landscape of Biotechnology market in tandem with its competitive terrain.

Favorable government initiative and growing demand for synthetic biology will drive the biotechnology industry growth over the forecast timeframe. Also rising demand for agro-based products should fuel global biotechnology market growth.

Decreasing cost of DNA sequencing from last couple of decades owing to the advances in the field of genomics will stimulate the global biotechnology market. Furthermore, increasing scarcity of natural resources across the globe should propel the industry growth.

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/6111

Biotechnology Market to exceed USD 775 billion by 2024 as per a new research report.

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/6111

Bio-agriculture segment will show the significant growth due to the inadequacy of the natural resources to meet the requirement of increasing global population. Increased crop yield as well as profitability are some of the advantages of genetically modified plants owing to which the segment is predicated to show significant growth in near future.

Bio-industrial segment will show growth as improved micro-organisms and enzymes are showing wide range of applications in chemical industry. Increasing demand for biofuels due to high price of natural oil and environmental concerns associated with the traditional fuels will further boost the biotechnology market.

However, the risk of food allergy and increased toxicity associated with the genetically modified organism and crops will limit the market growth over the forecast timeframe.

The tissue engineering focus on developing the cure for different chronic diseases. Increasing prevalence of chronic diseases is expected to drive the demand for tissue engineering and regeneration segment. Increasing cost of organ transplant and organ shortage will further boost the market growth as biotechnology provides better alternatives through tissue engineering technology.

PCR technology plays a key role in the DNA and genomics related research aimed at developing the better treatment for chronic diseases such as heart diseases and cancer. Increasing application of PCR in the field of diagnostics and several other fields such as archeology will boost the growth of the segment.

Major Highlights from Table of contents are listed below for quick lookup into Biotechnology Market report

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Biotechnology Industry Insights

Chapter 4. Company Profiles

Request Customization on This Report @ https://www.theresearchprocess.com/request-for-customization/6111

Go here to read the rest:
Biotechnology Market research, Industry Outlook, Current Trends and Forecast by 2025 - The Research Process

Baltimore,Maryland The U.S. Attorneys Office for the District of Maryland has seized mordernatx.com and regeneronmedicals.com, which purported to be the websites of actual biotechnology companies developing treatments for the COVID-19 virus, but instead appears to have been used to collect the personal information of individuals visiting the sites, in order to use the information for nefarious purposes, including fraud, phishing attacks, and/or deployment of malware. Individuals visiting those sites now will see a message that the site has been seized by the federal government and be redirected to another site for additional information.

The seizure of the domain names was announced by United States Attorney for the District of Maryland Robert K. Hur and Special Agent in Charge John Eisert of Homeland Security Investigations Baltimore.

The U.S. Attorneys Office and our law enforcement partners are committed to bringing to justice the criminals that try to take advantage of this global pandemic to line their pockets at the expense of the most vulnerable, said U.S. Attorney Robert K. Hur. I urge citizens to remain vigilant. Dont provide personal information or click on websites or links contained in unsolicited e-mails. Dont become a victim.

These individuals took advantage of fear during the global pandemic and attempted to steal personal information for nefarious purposes, said HSI Baltimore Special Agent in Charge John Eisert. From the cyber realm to counterfeit medication to financial crime, Homeland Security Investigations is committed to detecting, investigating, and disrupting all types of fraud related to the COVID-19 pandemic.

According to the affidavits filed in support of these seizures, these investigations began in early December 2020, after corporate security for one of the companies located the spoof website and contacted HSIs Intellectual Property Rights Center (IPRC) and the HSI Cyber Crimes Center (C3). The other website was identified during an ongoing HSI C3 operation targeting malicious websites. The cases were referred to HSI Baltimore for investigation.

Specifically, on December 10, 2020, the Global Head of Corporate Security for a biotechnology company headquartered in Cambridge, Massachusetts, which has developed a COVID-19 vaccine that is awaiting approval by the U.S. Food and Drug Administration (FDA), contacted HSI IPRC and C3 by e-mail to report that the companys Cybersecurity Team had detected the domain name mordernatx.com, a fraudulent replication of the companys website. A review of that websites online content displayed the name and trademarked logos for the biotechnology company. As detailed in the affidavit, the logos, markings, colors, and text of the mordernatx.com webpage showed no substantive differences from the genuine company websites landing page, other than the fact that the fraudulent website had a slight misspelling of the companys name. However, individuals who clicked on the Contact Us tab, were redirected to an entry form requesting information such as name, company/institution, title, phone, e-mail, and comments/questions. Additional investigation revealed that the mordernatx.com domain name was registered on about December 8, 2020, through a company headquartered in Kuala Lumpur, Malaysia, with no personal information for the registrar listed.

The second domain name seized, regeneronmedicals.com, was identified on December 9, 2020, during an ongoing HSI C3 investigation targeting malicious websites. Investigators found that the subject domain name contained the name and trademarked logos of, and was visually similar to, the webpage of a biotechnology company headquartered in Westchester County, New York, which was granted an emergency use authorization by the FDA for an antibody cocktail used to treat COVID-19 in high-risk patients with mild to moderate COVID-19. Further investigation revealed that the subject domain name contained two e-mail addresses and a telephone number not found on the official company website. The phone number appeared to be a Voice over IP (VOIP) number. In addition, the Contact Us page on the regeneronmedicals.com site directed Healthcare professionals, patients or caregivers requesting specific product information, reporting an adverse event or reporting a product complaint to contact the Medical Department at the VOIP number. The same Contact Us tab also provided a link to submit medical inquiries which directed users to a page that was different from the corresponding page on the authentic website. Investigators also found that the subject domain name was registered on December 6, 2020, and lists the registrant as an individual residing in Onitsha Anambra, Nigeria.

By seizing these sites, the government has prevented third parties from acquiring the names and using them to commit additional crimes, as well as prevented third parties from continuing to access the sites in their present form.

Federal law enforcement agencies are united in our efforts to fight against COVID-19 fraud. HSI has identifiedtipsto recognize and report COVID-19 fraud. If you believe you are a victim of a fraud or attempted fraud involving COVID-19, you may also call the National Center for Disaster Fraud Hotline at 1-866-720-5721 or for more information e-mail justice.gov/coronavirus.

United States Attorney Robert K. Hur commended HSI for its work in these investigations. Mr. Hur thanked Assistant U.S. Attorneys Sean Delaney, Aaron S.J. Zelinsky, and Thomas M. Sullivan, who are handling these cases.

Like Loading...

Related

More here:
Maryland US Attorney's Office Seizes Two Domain Names Purporting to be Websites of Biotechnology Companies Developing Treatments for Covid-19 - The...

The Pharmaceutical And Biotechnology Machines Marketreport enlists essential and realistic data with regards to the market situation. The current situation of the Pharmaceutical And Biotechnology Machines market, alongside its preceding overall performance as properly as future scope are included in the report. It demonstrates a quick summary of industry facts and the key nomenclature of the market. The report has highlights, regularly occurring performers, from the global market together with their contribution to the market to decide their growth inside the estimated time.

Furthermore, The report covers key strategic points regarding developments in the market which include acquisitions & mergers, agreements, partnerships, new type launches, research & development, collaborations & joint ventures, regional growth of predominant contributors concerned in the Pharmaceutical And Biotechnology Machines market on a global and regional basis.

Get Sample Report + All Related Graphs & Charts: https://www.stratagemmarketinsights.com/sample/19841

It Furnishes detailed information on the factors that will restrain the growth of Pharmaceutical And Biotechnology Machines manufacturers: Air Liquide, Linde Healthcare, Praxair, Air Products, Taiyo Nippon Sanso, Matheson Gas, Atlas Copco AB, Messer Group, SOL Group, Norco, Sicgil Limited, Shenzhen Gaofa, Shenwei Medical, Beijing Orient, Nanning Lantian

Pharmaceutical And Biotechnology Machines Market COVID-19 Impact Analysis:

As the world is still dealing with the COVID-19 situation, many of the countries have slowly started to revive their economic situation by starting their trade and businesses. There has been an enormous loss in these few months both in terms of economy and human lives. As the WHO has already suggested that there are very less chances that the virus will completely go, hence we will have started living with it. Many of the drug companies are getting a positive response to their COVID-19 vaccines, but there is still time for their availability in the global market.

Research Methodology:

The process of market research at SMI is iterative in nature and generally follows the following path. Information from secondary is used to construct records models, in addition, the consequences got from data models are validated from essential participants. Then cycle repeats where, in accordance with inputs from important participants, additional secondary research is completed and new information is once more integrated into the data model. The process continues until the favored degree of facts is no longer generated.

To calculate the Pharmaceutical And Biotechnology Machines market size, the report considers the revenue generated from the sales of the market providers. The revenue generated from the sales of the market is calculated through essential and secondary research. The key players working in the market throughout the globe are recognized via secondary research and a corresponding detailed analysis of the top vendors in the market is done. The market size calculation additionally consists of clinical trial phase segmentation that decided the usage of secondary sources and verified thru primary sources.

The report covers exhaustive analysis on:

Regional analysis includes:

Report Highlights:

Key Question and Answers in the Study:

Get assured Discount on this Report (UsePrompocodeCHRISTMAS25):https://www.stratagemmarketinsights.com/discount/19841

[**Note: To avail of this offer Specify this Promo code in precise requirement.]

Contact Us:

Mr. ShahStratagem Market InsightsTel:USA +1-415-871-0703JAPAN +81-50-5539-1737UK +44-203-289-4040Email: [emailprotected]

Explore BySJ

Link:
Pharmaceutical And Biotechnology Machines Market Thriving Impulsive Hike With Key Players - LionLowdown

Oct. 13, 2020 12:00 UTC

PHILADELPHIA--(BUSINESS WIRE)-- Aro Biotherapeutics today announced the appointments of Christopher K. Mirabelli, Ph.D., to its Board of Directors and Masad J. Damha, Ph.D., to its Scientific Advisory Board. Drs. Mirabelli and Damha will provide strategic and scientific counsel on the development of novel Centyrin-RNA therapeutic candidates.

We are excited to welcome Chris, a well-recognized leader in drug development, to our Board of Directors. As the founder of multiple successful biotechnology companies, and an industry veteran with demonstrated experience in the development of new therapies, his insight and guidance will be invaluable as we advance the development of our pipeline of Centyrin-based therapeutic candidates, said Susan Dillon, Ph.D., Co-Founder and Chief Executive Officer of Aro.

Dr. Mirabelli has spent over 35 years in the pharmaceutical and biotechnology industries as a research scientist, senior executive, and venture capital investor. Currently, he is a managing director of the venture capital firm HealthCare Ventures. Dr. Mirabelli is currently Chairman of the Board of Directors of Leap Therapeutics, where he was the Chief Executive Officer from its founding in 2015 until 2020. Previously, Dr. Mirabelli was Chief Executive Officer and Chairman of the Board of Directors of LeukoSite from its founding in 1993 until its acquisition by Millennium Pharmaceuticals in 1999. Dr. Mirabelli was also a Co-Founder of Ionis Pharmaceuticals. He began his industry career in R&D at SmithKline & French Laboratories, and earned his Ph.D. in Molecular Pharmacology from Baylor College of Medicine and his B.S. in Biology from State University of New York (SUNY) at Fredonia.

I am looking forward to serving on Aros Board of Directors and working with Sue and her team to further advance their proprietary drug-targeting technology, commented Dr. Mirabelli. The use of antibodies to target drugs to sites of disease in patients has many limitations. Aros novel approach to overcoming these barriers is unique, and Im excited to contribute to the continued development of their pipeline of next-generation biotherapeutic candidates.

We are pleased to have Masad join Aros Scientific Advisory Board. His work in nucleic acid drug discovery and development has been at the forefront of oligonucleotide research, and his scientific insights will be instrumental as we continue to leverage the promise of Centyrins to achieve new therapeutic mechanisms of action, said Karyn ONeil, Ph.D., Co-Founder and Chief Scientific Officer of Aro.

Dr. Damha is a Distinguished James McGill Professor of Chemistry at McGill University. His research group focuses on synthesis and structural analyses of chemically modified oligonucleotides directed toward biomedical and diagnostic applications. His 200+ publications and dozens of issued patents have been widely cited and used in both fundamental sciences and oligonucleotide-based therapeutic applications. Dr. Damha is the recipient of several awards from the Canadian Society for Chemistry, the Queen Elizabeth II Diamond Jubilee Medal (Governor General of Canada), and McGills Fessenden Professorship in Science Innovation. He is currently President of the International Society of Nucleosides, Nucleotides, Nucleic Acids, and he has served as President of the Oligonucleotide Therapeutics Society. Dr. Damha was awarded a Ph.D. in Organic Chemistry and B.Sc. in Chemistry from McGill University.

Dr. Damha commented, I am very pleased to join Aro Biotherapeutics Scientific Advisory Board and contribute to the development of innovative therapies that enable efficient and specific delivery of nucleic acid conjugates that address important disease targets.

About Aro Biotherapeutics

Aro is a biotechnology company focused on the research and development of a new generation of protein biologics called Centyrins. The company is developing a wholly-owned pipeline of Centyrins and is working with leaders in the industry on leveraging Centyrins for tissue-specific targeting of therapeutics, including nucleic acid drugs for a diverse set of diseases. For more information, visit http://www.arobiotx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201013005040/en/

View original post here:
Aro Biotherapeutics Appoints Biotechnology Executive Dr. Christopher Mirabelli to its Board of Directors and Nucleic Acid Therapeutics Expert Dr....

On November 22, 2020, Judge Howard C. Nielson, Jr. of the United States District Court for the District of Utah dismissed with prejudice a putative class action asserting claims under the Securities Exchange Act of 1934 against a biotechnology company and certain of its executives. In re PolarityTE, Inc. Sec. Litig., No. 2:18-cv-00510, 2020 WL 6873798 (D. Utah Nov. 22, 2020). Plaintiffs alleged that the company made material misstatements in the course of a reverse merger and in subsequent SEC filings. The Court held that plaintiffs failed to adequately allege falsity with respect to certain challenged statements and failed to establish loss causation for the remainder.

Plaintiffs alleged that the company made misstatements concerning: (1) the companys registration of a product with the FDA under a particular provision of the Public Health Service Act, which the company ultimately abandoned and refiled under a different provision after the FDA disagreed with the companys original approach, id. at *3-4; (2) the quality of the companys manufacturing facilities, in light of violations reported by the FDA, id. at *4; (3) the companys patents, including with respect to an application for which the company had received a non-final rejection a week before the merger closed and subsequently received a final rejection, id. at *2; and (4) the non-existence of any pending or contemplated government proceedings against the company, in light of the company having received a document request from the SEC after reporting to the SEC suspicious trading of its stock. Id. at *5.

The Court first assessed the companys statements regarding its products registration with the FDA and concluded that plaintiffs likely failed to allege a material misstatement, id. at *8, because the challenged statements were either true (to the extent they preceded the companys announcement that it intended to proceed under a different regulatory scheme) or constituted statements of opinion as to whether it was appropriate to pursue registration under the framework originally chosen by the company. Id. at *8. The Court further stated that plaintiffs likely fail[ed] to allege that the company lacked any factual basis for its opinions, thus rendering the opinions nonactionable. Id.

The Court did not, however, definitively determine whether a material misrepresentation had been alleged with regard to the registration issues, relying instead on its conclusion that plaintiffs failed to allege loss causation because the purported corrective disclosures (articles published regarding the company) relied on information previously disclosed to the market. Id. at *9. While noting that the Tenth Circuit had not squarely addressed the issue, the Court observed that other Circuits have held that, to qualify as a corrective disclosure, the disclosure must reveal non-public information. Id. at *6. Here, however, the articles plaintiffs relied upon did not actually reveal any then-undisclosed facts; instead, all the materials the articles referenced were publicly available. Id. at *9. Furthermore, the Court explained that, although some courts have ruled that expert analysis of publicly available information could constitute a corrective disclosure, there was no indication that the authors of the articles relied upon by plaintiffs had any expertise beyond that of careful investors. Id.

The Court next assessed plaintiffs allegations that the companys statements concerning the quality of its manufacturing facilities were materially misleading because the FDA had reported violations in July 2018. Id. at *10. The Court concluded that the challenged statements were either puffery or, in any event, plaintiffs failed to allege how the statements were rendered false by the FDAs findings. Id. While noting that the company had received the FDAs report before the challenged statements were made, the Court emphasized that the FDA had not made a final determination at the time, and that ultimately the FDA closed the inspection indicating that the allegedly objectionable conditions [did] not meet the threshold of regulatory significance. Id. Furthermore, the Court noted that two months passed between the FDAs inspection and the statements in question, during which time it appear[ed] that [the company] had made at least some improvements to its processes in response to the FDAs concerns. Id. at *11. In light of those circumstances, the Court concluded that the FDAs report does not support a reasonable inference that the individual who made the statements did not believe the puffing statements of corporate optimism. Id. at *11.

Turning to statements concerning the companys patents, the Court first noted that statements by the company that its products were subject to pending patent applications were true. Id. To the extent the company erroneously described certain technology as patented, the Court reasoned that those statements were immaterial because other company statements made clear that the technology at issue was not presently protected by existing patents but was rather the subject of pending patent applications. Id. The Court reasoned that, to the extent these statements were conflicting, that would have given a reasonable investor sufficient pause to warrant independent verification. Id. at *12. While the Court thus concluded that plaintiffs likely failed to adequately allege a material misstatement, id. at *11, it held that, regardless, plaintiffs again failed to adequately allege loss causation because the articles relied on as corrective disclosures were based on previously available information. Id. at *12.

Finally, the Court rejected plaintiffs argument that the companys statements about not being subject to any pending or contemplated governmental proceedings were false because the company had received a document request from the SEC. Id. at *13. The Court concluded that an isolated document request is not an investigation, and, in context, it was not reasonable to believe the company should have expected the SEC to conduct an investigation based on the request received. Id. The Court also observed that, even if an investigation had been contemplated, the companys statement was not false because [a]n investigation on its own is not a pending legal proceeding, and the SEC had not informed the company that it was contemplating further action. Id.

Because plaintiffs had not filed a motion seeking leave to amend, the Court dismissed the action with prejudice. Id.

Links & Downloads -

In re PolarityTE, Inc. Sec. Litig.

[View source.]

See original here:
Utah District Court Dismisses Putative Securities Class Action Against Biotechnology Firm For Failure To Allege Falsity And Loss Causation - JD Supra

Oct-2020 Updated Report: Final Report will add the analysis of the impact of COVID-19 on this industry.

Global White Biotechnology Market Research Report presents a competitive assessment and detailed statistical analysis on White Biotechnology Industry prospects. The White Biotechnology Report will enlighten the readers with market dynamics and market trends to provide a holistic market overview. The key aspects of White Biotechnology Industry like market growth, market dynamics, threats and cost structures are presented in the report. The emerging market trends, latest development, R&D status, and key vendors are analysed at depth. The White Biotechnology report is segmented based on product type, application and top geographical regions.

To Understand How Covid-19 Impact on this industry. Get Free Sample Report:

https://www.reportspedia.com/report/chemicals-and-materials/global-white-biotechnology-market-research-report-2020,-segment-by-key-companies,-countries,-types,-applications-and-forecast-2021-to-2026/73289#request_sample

Major players covered in this report:

DSMBayerDSMEvonikDow ChemicalsHenkelBASFDuPontLANXESS

Global White Biotechnology Market Segmentation:

By Type:

BiofuelsBiomaterialsBiochemicalsIndustrial Enzymes

By Application:

BioenergyFood & Feed AdditivesPharmaceutical IngredientsPersonal Care & Household Products

The future White Biotechnology Industry predictions explain the forecast market values, industry progress, upcoming plans and policies. Also, the volume, value and consumption forecast view is presented from 2020-2026. The strategies implemented by top White Biotechnology players, as well as historic and present market performance is portrayed in this report. The White Biotechnology fundamental market overview, market share, import-export status, and pricing structure is presented. The report begins with White Biotechnology research objectives, definition, market scope and size estimation. The growth rate from 2015-2026 and complete White Biotechnology Industry picture is covered.

Get Up to 40% Off on purchasing this report, Ask Here for Discount @:

https://www.reportspedia.com/discount_inquiry/discount/73289

All top product types, applications and regions namely North America, Europe, Asia-Pacific, South America, and Middle East & Africa are analysed. A complete market outlook from 2015-2026 with country-level analysis for above-mentioned regions is covered in the report. The top countries analysed in the report include United States, Canada, Mexico, France, Germany Italy, UK, Russia, China, Korea, Japan, India, Brazil, South Africa, Egypt, Turkey and Saudi Arabia are profiled in the report. Other regions/countries can be added based on user requirements.

Next segment explains the White Biotechnology market dynamics presenting the opportunities, risks and market driving forces. Also, the top manufacturers profile analysed in the study explains their business portfolio, market growth, market share for every type and application as well as their geographical presence. A complete estimation of sales margin, price, revenue share and gross margin is explained. The sales and marketing channels of White Biotechnology, traders, distributors and dealers of White Biotechnology Market are evaluated completely.

Inquire Before Buying Or Ask For More Details:

https://www.reportspedia.com/report/chemicals-and-materials/global-white-biotechnology-market-research-report-2020,-segment-by-key-companies,-countries,-types,-applications-and-forecast-2021-to-2026/73289#inquiry_before_buying

The Primary Objectives of White Biotechnology Market Research Report Are As Follows:

The top-down and bottom-up approach is implied to study the White Biotechnology Market statistics and analytical details. The data is presented in the form of graphs, tables, and figures to provide ease of understanding. The SWOT analysis, investment return analysis and mergers & acquisitions in White Biotechnology Industry are stated. The changes in business structure, plans & policies and emerging players are analysed in detail. This report will be useful for all market participants and business consultants to understand White Biotechnology market trends, growth drivers and challenges.

View Full Table Of Content: @

https://www.reportspedia.com/report/chemicals-and-materials/global-white-biotechnology-market-research-report-2020,-segment-by-key-companies,-countries,-types,-applications-and-forecast-2021-to-2026/73289#table_of_contents

Contact Us:

Name: Alex White

Phone: US: +1(806)4400782/ UK: +44 33 3303 4979

Email: [emailprotected]

Original post:
Global White Biotechnology Market Growth Trajectory, CAGR value, Market Share and Revenue Analysis and Forecast Till 2026 - TechnoWeekly

Globe Newswire

Pixium Vision Hosting Key Opinion Leader Webinar on the Prima System for Atrophic Dry Age-related Macular Degeneration (dry-AMD) Paris, France October 16TH , 2020 7:30 am CET - Pixium Vision (Euronext Growth Paris - FR0011950641 - ALPIX), a company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, today announced that it will host a key opinion leader (KOL) call on the Prima System for Atrophic Dry Age-related Macular Degeneration (dry-AMD) on Friday, October 30, 2020 at 10:30am Eastern Time. The webinar will feature a presentation by KOLs Jos-Alain Sahel, M.D., University of Pittsburgh School of Medicine, and Lisa C. Olmos de Koo, M.D., University of Washington, who will discuss the current treatment landscape and unmet medical need in treating patients with Advanced Atrophic Dry Age-related Macular Degeneration (dry-AMD). Drs. Sahel and Olmos de Koo will be available to answer questions following the formal presentation. Pixium Vision's management team will give an update on their Prima Bionic Vision System.Composed of three main components: a wireless retinal implant, a pair of glasses with incorporated camera and digital projector, and a pocket processor analyzing the images and transforming them into signals sent wirelessly to the retinal implant via the digital projector. The Prima System intends to partially replace the normal physiological function of the eyes photoreceptor cells by electrically stimulating the nerve cells of the inner retina, which then transmit the visual information to the brain via the optic nerve. To register for the call, please click here. Jos-Alain Sahel, MD, is Distinguished Professor Chairman of the Department of Ophthalmology at the University of Pittsburgh School of Medicine and the Eye & Ear Foundation Endowed Chair, and Director of the UPMC Eye Center. He is an Exceptional Class Professor of Ophthalmology at the Medical School of Sorbonne Universit. He is the Founder and Director of The Vision Institute (Sorbonne/Inserm/CNRS), Paris, France. He heads the French National Reference Center for Rare Retinal Dystrophies and coordinates the Paris-based Ophthalmology Clinical Investigation Center, overseeing more than 80 clinical trials, some of them first in man within the most advanced areas of biomedical technologies, e.g. retinal implants, gene therapy, stem cell therapies and optogenetics. He is a clinician-scientist conducting research on vision restoration in retinal degenerative diseases, focusing on cellular and molecular mechanisms underlying retinal degeneration, development of treatments for currently untreatable retinal diseases by pharmacological treatments, gene therapy, stem-cell therapy, and retinal prosthesis. He has co-authored over 590 peer-reviewed articles and holds more than 40 patents. He received numerous awards, e.g. the Foundation Fighting Blindness Trustee Award, the Alcon Research Institute Award for Excellence in Vision Research, the Grand Prix NRJ-Neurosciences-Institut de France, the Llura Liggett Gund Award from Foundation Fighting Blindness. He was elected to the Academia Ophthalmologica Internationalis, the Academy of Sciences-Institut de France, the German National Academy of Sciences Leopoldina, the National Academy of Technologies of France and the Association of American Physicians. He holds an Honoris Causa doctorate from the University of Geneva and was an invited chair at the Collge de France. Dr. Sahel was a co-founder of Fovea Pharmaceuticals, StreetLab, GenSight Biologics, Pixium Vision, Sparing Vision. He is a member of several Editorial Boards, including Science Translational Medicine. Lisa C. Olmos de Koo, M.D., M.B.A., is an Associate Professor of Ophthalmology at the University of Washington in Seattle, where she serves as chief of the Retina Division. She received her bachelors degree in chemistry from Harvard University. During her undergraduate years, she spent summers conducting basic science research in ophthalmic genetics at the National Eye Institute, National Institutes of Health (NIH) in Bethesda, MD. She then earned her medical degree from Baylor College of Medicine in Houston, TX, along with an MBA from Rice University. She completed her internship at Georgetown University, with rotations at the Walter Reed Armed Forces Institute of Pathology (AFIP) as well as at the LV Prasad Eye Hospital in Hyderabad, India. Following the completion of her ophthalmology residency and vitreoretinal fellowship at the world-renowned Bascom Palmer Eye Institute of the University of Miami, in Miami, FL, Dr. Olmos was selected to serve a prestigious one-year term as Chief Resident and Co-Director of Ocular Trauma at Bascom Palmer. One of the few implanting surgeons worldwide for the Argus II retinal prosthesis, Dr. Olmos formerly served as Primary Investigator for the Argus II device clinical trials while she was on faculty at the Doheny Eye Institute and the Roski Eye Institute of the University of Southern Californias Keck School of Medicine in Los Angeles, CA. Dr. Olmos has a special interest in ophthalmic education, currently serving as Retina Fellowship Program Director at the UW, a position she previously held at USC. She is the editor of a quarterly column in Retina Specialist Magazine and serves as an adjunct professor of Ophthalmology at Seoul National University in South Korea. She sits on the Board of Directors of the American Society of Retina Specialists (ASRS). She regularly lectures at both national and international meetings. ABOUT PIXIUM VISIONPixium Visions mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy. Pixium Visions bionic vision systems require a surgical procedure and a rehabilitation period. Pixium Vision is conducting clinical feasibility studies of its Prima system, its miniaturized wireless sub-retinal implant, in patients who have lost their sight due to retinal degeneration associated with the dry form of Age- Related Macular Degeneration (AMD). Pixium Vision works closely with world-renowned academic partners, such as UPMC in Pittsburgh, Stanford University in California, Bascom Palmer Eye Institute of the University of Miami, Institut de la Vision in Paris, Moorfields Eye Hospital in London and Institute of Ocular Microsurgery (IMO) in Barcelona. The company is EN ISO 13485 certified. Pixium Vision has been qualified as an Innovative Company by Bpifrance Forward Looking StatementsThis press release, implicitly or expressly, contains certain forward-looking statements concerning Pixium Vision and its business. Such statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, financial conditions, performance or achievements of Pixium Vision to be materially different from the results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Pixium Vision issues this press release as at this date and does not undertake to update any forward-looking statements contained herein, whether in response to new information, future events or otherwise. For a description of the risks and uncertainties that could cause the actual results, financial conditions, performance or achievements of Pixium Vision to differ from those contained in the forward-looking statements, please refer to section 3 Risk Factors of the Companys reference document, which was filed with the Autorite des Marches Financiers under number D.20-0350 on 24 April 2020, and which can be viewed on the websites of the Autorite des Marches Financiers - AMF (www.amf-france.org) and Pixium Vision (www.pixium-vision.com). Contacts

Read the original post:
B.R.A.I.N. Biotechnology Research And Information Network AG: Two experts join the BRAIN AG Supervisory Board - Yahoo Finance UK

A rating of 78 puts Rapt Therapeutics Inc (RAPT) near the top of the Biotechnology industry according to InvestorsObserver. Rapt Therapeutics Inc's score of 78 means it scores higher than 78% of stocks in the industry. Rapt Therapeutics Inc also received an overall rating of 66, putting it above 66% of all stocks. Biotechnology is ranked 23 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 66 means the stock is more attractive than 66 percent of stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Rapt Therapeutics Inc (RAPT) stock is trading at $36.59 as of 1:24 PM on Friday, Oct 9, an increase of $2.76, or 8.16% from the previous closing price of $33.83. The stock has traded between $34.01 and $37.06 so far today. Volume today is light. So far 102,755 shares have traded compared to average volume of 257,588 shares.

Click Here to get the full Stock Score Report on Rapt Therapeutics Inc (RAPT) Stock.

View original post here:
Should You Buy Rapt Therapeutics Inc (RAPT) in Biotechnology Industry? - InvestorsObserver